TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer
-
Published:2024-06
Issue:
Volume:134
Page:112224
-
ISSN:1567-5769
-
Container-title:International Immunopharmacology
-
language:en
-
Short-container-title:International Immunopharmacology
Author:
Xiang Kanghui,
Zhang Minghui,
Yang Bowen,
Liu Xu,
Wang Yusi,
Liu Hengxin,
Song Yujia,
Yuan Yonghui,
Zhang Lingyun,
Wen TiORCID,
Zhang Guang-WeiORCID
Reference49 articles.
1. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology;Ajani;J. Natl. Compr. Canc. Netw.,2022
2. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N. Engl. J. Med.,2008
3. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial;Koizumi;Lancet Oncol.,2008
4. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
5. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献